2020 AASLD Abstract Categories and Descriptors (The Liver Meeting®)

**Acute Liver Failure and Artificial Liver Support**
AO1 Acute Liver Failure and Artificial Liver Support

**Advanced Practice Providers (NP, PA, RN, PharmD, etc.)**
BO1 Behavioral and Quality Issues
BO2 Practice Issues

**Alcohol-associated Liver Diseases: Clinical and Experimental**
CO1 Alcohol-associated Liver Diseases: Clinical and Experimental

**Biliary Physiology, Transport, Cholangiocyte Biology, and Experimental Cholestasis**
DO1 Transport, Bilirubin, Cholesterol, Lipids, and Bile Salts
DO2 Cholangiocyte Biology
DO3 Experimental Cholestasis

**Cell and Molecular Biology**
EO1 Cell Structure and Function
EO2 Signal Transduction and Nuclear Receptors
EO3 Gene Expression and Therapy
EO4 Stem Cell Biology

**Genomics and Precision Medicine**
FO1 Genomics and Precision Medicine

**Gut Liver Axis and Microbiome**
GO1 Gut Liver Axis and Microbiome

**Health Services Research**
HO1 Health Care Delivery/Access/Quality
HO2 Cost-Effectiveness and Economics of Care
HO3 Patient Centered Outcomes Research

**Hepatitis B**
IO1 Virology, Pathogenesis, and Immunology
IO2 Diagnostics and Biomarkers
IO3 Epidemiology, Prevention, Natural History
IO4 Therapeutics: Approved Agents
IO5 Therapeutics: New Agents

**Hepatitis C**
JO1 Virology, Pathogenesis, and Immunology
JO2 Diagnostics, Epidemiology, and Natural History
JO3 Therapeutics: New Agents
JO4 Therapies: General Populations
JO5 Therapies: Unique Populations

**Hepatitis: Other Infections**
KO1 Hepatitis: Other Infections
Hepatobiliary Neoplasia
LO1 Experimental Hepatocarcinogenesis
LO2 Diagnostics and Liver Imaging
LO3 Clinical: Hepatocellular Carcinoma and Cholangiocarcinoma

Hepatotoxicity
MO1 Pathogenesis and Mechanisms
MO2 Drug Metabolism, Toxicity and Therapeutics
MO3 Predictors of Drug Toxicity

Human Cholestatic and Autoimmune Liver Diseases
NO1 PBC/PSC and Other Cholestatic Disease
NO2 Autoimmune Liver Disease

Inflammation and Immunobiology
OO1 Animal Models
OO2 Innate Immunity
OO3 Adaptive Immunity
OO4 Mechanisms of Injury

Liver Fibrogenesis and Non-Parenchymal Cell Biology
PO1 Basic Fibrosis Research and Stellate Cell Biology
PO2 Imaging and Noninvasive Markers of Liver Disease
PO3 Clinical and Translational Fibrosis Research

Liver Transplantation and Liver Surgery
QO1 Cellular Immunobiology, Preservation, and Cell Transplantation
QO2 Donor and Allocation Issues, Living Donor and Split Liver Transplantation, and Hepatobiliary Surgery
QO3 Immunosuppression, Outcomes, Complications
QO4 Viral Hepatitis

Metabolic and Genetic Disease
RO1 Hemochromatosis, Wilson Disease, and α-1 Antitrypsin Deficiency

NAFLD and NASH
SO1 Experimental: Basic
SO2 Experimental: Clinical
SO3 Epidemiology and Natural History, Prevention and Outcomes
SO4 Diagnostics and Biomarkers
SO5 Therapeutics: Pharmacologic and Other

Pediatric Hepatology
TO1 Pediatric Liver Disease – Basic Science
TO2 Biliary Atresia and Cholestasis
TO3 Viral and Autoimmune Hepatitis
TO4 Metabolic and Genetic Diseases
TO5 Pediatric Liver Transplantation
Portal Hypertension and Other Complications of Cirrhosis
UO1 Experimental
UO2 Ascites, Renal Dysfunction, and Hepatorenal Syndrome
UO3 Varices and Bleeding
UO4 Encephalopathy and Other Complications
UO5 Infections and Acute on Chronic Liver Failure

Training and Education (Career Development)
VO1 Training and Education (Career Development)

COVID-19 and the Liver
1. Basic
2. Clinical/Translational
3. Transplant
4. Health Services